MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
Rhea-AI Summary
MeiraGTx (NASDAQ: MGTX) will present 3-year data from the open-label Phase 1 AQUAx study of AAV-hAQP1 for treatment of persistent grade 2/3 radiation-induced xerostomia on April 16, 2026 at 8:00 a.m. ET.
The presentation includes cohort-level and individual patient data for PRO Xerostomia Questionnaire (XQ) and objective Unstimulated Whole Saliva Flow Rate (UWSFR) out to three years for bilateral and unilateral cohorts, an investigator discussion of disease burden and treatment administration, commercial opportunity commentary, and a Q&A. A live webcast and replay will be available on the company investor website.
Positive
- None.
Negative
- None.
News Market Reaction – MGTX
In the Apr 14 session, MGTX gained 17.24%, reflecting a significant positive market reaction. Argus tracked a peak move of +18.8% during that session. Our momentum scanner triggered 54 alerts that day, indicating high trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | BTD & earnings | Positive | -1.2% | Breakthrough Therapy designation and full-year 2025 financial results with major partnerships. |
| Feb 03 | License deal | Positive | +2.7% | Exclusive license agreement with ZipBio for first-in-class AAV gene therapy in GA. |
| Nov 20 | Conference data | Positive | -2.0% | Selective ROCK2 obesity data presentation and obesity program discussion at a healthcare conference. |
| Nov 13 | Earnings update | Negative | -4.6% | Q3 2025 financials with lower service revenue and cash balance plus program updates. |
| Nov 10 | Strategic collaboration | Positive | +0.9% | Major Eli Lilly ophthalmology collaboration with $75M upfront and milestone potential. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The stock has shown mixed reactions: collaborations and licenses often aligned positively with price, while some major designations and data events saw short-term sell-offs.
Over the last six months, MeiraGTx reported multiple strategic and clinical milestones. A $75M ophthalmology collaboration with Eli Lilly and additional Hologen/J&J partnerships underscored its partnering strategy. Regulatory momentum included Breakthrough Therapy and RMAT designations for AAV2‑hAQP1 and AAV‑GAD, alongside progress in the pivotal AQUAx2 program. Financial updates showed increased revenue from a $75M Lilly upfront and improved net loss versus 2024. Against this backdrop, the new three‑year Phase 1 xerostomia data presentation continues the focus on AAV‑hAQP1 and long‑term outcomes.
Key Terms
xerostomia questionnaire (xq) medical
unstimulated whole saliva flow rate (uwsfr) medical
open-label medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study
- Cohort-level data and individual patient data from bilateral and unilateral cohorts will be presented for both PRO and objective measures.
LONDON and NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced it will host a conference call and webcast to present 3-year data from the long-term follow-up of patients in the Phase 1 study of AAV-hAQP1 for the treatment of persistent grade 2/3 moderate to severe radiation-induced xerostomia (RIX) on Thursday, April 16, 2026, at 8:00 a.m. ET.
The presentation will include:
- Three-year data from the long-term follow-up of the patients in the open-label Phase 1 AQUAx clinical study.
This data will include:
- PRO Xerostomia Questionnaire (XQ) data out to 3 years post treatment with AAV-hAQP1 for both bilateral and unilateral cohorts
- Objective Unstimulated Whole Saliva Flow Rate (UWSFR) data out to 3 years
- Full cohort data, as well as individual patient data out to 3 years for both the XQ and UWSFR
- Study Investigator discussion of disease burden, patient experience, and treatment administration
- Commercial opportunity
A question-and-answer session will follow the formal presentation.
To register and attend the event, please click here.
A live webcast of the call, as well as a replay, will be available on the Investors page of the Company’s website at www.investors.meiragtx.com/.
About the Phase 1 AQUAx Clinical Trial
The Phase 1 AQUAx clinical trial is an open-label, non-randomized, dose escalation trial designed to evaluate the safety of MeiraGTx’s investigational gene therapy AAV-hAQP1 when administered via Stensen's duct to one or both parotid glands in patients who have been diagnosed with grade 2 or 3 radiation-induced xerostomia and who have remained cancer-free for at least five years (or at least two years if HPV+) after receiving radiation treatment for head and neck cancer. Primary endpoint of the trial is safety, with efficacy endpoints including patient-reported measures of xerostomia symptoms and the evaluation of the change in parotid gland salivary output after treatment with AAV-hAQP1. The 12-month data have been released and presented publicly. Patients treated in the Phase 1 AQUAx study are followed for 5 years after the one-time administration of AAV-hAQP1.
About MeiraGTx
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline with four late-stage clinical programs. Each of these programs uses local delivery of small doses, resulting in disease-modifying effects in both inherited and more common diseases, in the eye, Parkinson’s disease, and radiation-induced xerostomia. MeiraGTx uses its innovative technology in optimization of capsids, promoters, and novel translational control elements to develop best-in-class, potent, safe viral vectors. MeiraGTx’s broad pipeline is supported by end-to-end in-house manufacturing. MeiraGTx has built the most comprehensive manufacturing capabilities in the industry, with 5 facilities globally, including two that are licensed for GMP viral vector production and a GMP QC facility with clinical and commercial licensure. In addition, MeiraGTx has developed a proprietary manufacturing platform process over 9 years based on more than 20 different viral vectors with leading yield and quality aspects and commercial readiness. Uniquely, MeiraGTx has developed a novel technology for in vivo delivery of any biologic therapeutic using oral small molecules. This transformative riboswitch gene regulation technology allows precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing the riboswitch platform on the regulated in vivo delivery of metabolic peptides, including GLP-1, GIP, Glucagon, Amylin, PYY, and Leptin, as well as cell therapy, CAR-T for liquid and solid tumors and autoimmune diseases, and additionally, PNS targets addressing long-term intractable pain. MeiraGTx has developed the technology to apply genetic medicine to common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains high.
For more information, please visit www.meiragtx.com
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding our product candidate development and anticipated milestones regarding our pre-clinical and clinical data, reporting of such data and the timing of results of data and regulatory matters, as well as statements that include the words “expect,” “will,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “could,” “should,” “would,” “continue,” “anticipate,” “eligible” and similar statements of a future or forward-looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, our incurrence of significant losses; any inability to achieve or maintain profitability, raise additional capital, repay our debt obligations, identify additional and develop existing product candidates, successfully execute strategic transactions or priorities, bring product candidates to market, expansion of our manufacturing facilities and processes, successfully enroll patients in and complete clinical trials, accurately predict growth assumptions, recognize benefits of any orphan drug or rare pediatric disease designations, retain key personnel or attract qualified employees, or incur expected levels of operating expenses; the impact of pandemics, epidemics or outbreaks of infectious diseases on the status, enrollment, timing and results of our clinical trials and on our business, results of operations and financial condition; failure of early data to predict eventual outcomes; failure to obtain FDA or other regulatory approval for product candidates within expected time frames or at all; the novel nature and impact of negative public opinion of gene therapy; failure to comply with ongoing regulatory obligations; contamination or shortage of raw materials or other manufacturing issues; changes in healthcare laws; risks associated with our international operations; significant competition in the pharmaceutical and biotechnology industries; dependence on third parties; risks related to intellectual property; changes in tax policy or treatment; our ability to utilize our loss and tax credit carryforwards; litigation risks; and the other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, unless required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Contacts
Investors:
MeiraGTx
Investors@meiragtx.com
or
Media:
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com
